12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AV-101: Phase I data

A double-blind, placebo-controlled Phase I trial in healthy volunteers showed that single doses of AV101 were well tolerated with no serious...

Read the full 82 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >